A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

NCT06850051 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Influenza Vaccination
Respiratory Syncytial Virus Vaccination
Parainfluenza Vaccination
Human Metapneumovirus Vaccination

Interventions

BIOLOGICAL: TIV-HA Vaccine formulation 1 at low dose
BIOLOGICAL: TIV-HA formulation 1 at high dose
BIOLOGICAL: TIV-HA formulation 2 at low dose
BIOLOGICAL: TIV-HA formulation 2 at high dose
BIOLOGICAL: RSV/hMPV/PIV3 formulation 2 at low dose
BIOLOGICAL: RSV/hMPV/PIV3 formulation 1 at high dose
BIOLOGICAL: RSV/hMPV/PIV3 formulation 2 at high dose
BIOLOGICAL: RSV/hMPV/PIV3 formulation 1 at low dose
BIOLOGICAL: RIV4 (Supemtek®)

Sponsor

Sanofi